Assidicky, R. Et Al. 2022. Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer. BREAST CANCER RESEARCH AND TREATMENT , vol.193, no.2 , 331-348.

Assidicky, R., Tokat, U. M., Tarman, I. O., Saatci, O., Ersan, P. G., Raza, U., ... Ogul, H.(2022). Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer. BREAST CANCER RESEARCH AND TREATMENT , vol.193, no.2, 331-348.

Assidicky, Ridho Et Al. "Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer," BREAST CANCER RESEARCH AND TREATMENT , vol.193, no.2, 331-348, 2022

Assidicky, Ridho Et Al. "Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer." BREAST CANCER RESEARCH AND TREATMENT , vol.193, no.2, pp.331-348, 2022

Assidicky, R. Et Al. (2022) . "Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer." BREAST CANCER RESEARCH AND TREATMENT , vol.193, no.2, pp.331-348.

@article{article, author={Ridho Assidicky Et Al. }, title={Targeting HIF1-alpha/miR-326/ITGA5 axis potentiates chemotherapy response in triple-negative breast cancer}, journal={BREAST CANCER RESEARCH AND TREATMENT}, year=2022, pages={331-348} }